(Source: Actelion Ltd) Approval granted by Medsafe in New Zealand on 17 March 2016 and by the TGA in Australia on 18 March 2016 ALLSCHWIL, SWITZERLAND - 22 March 2016 - Actelion Ltd (SIX: ATLN) announced today that the Therapeutic Goods Administration (TGA) of Australia and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) have granted approval for the orally active selective IP prostacyclin receptor agonist Uptravi® (selexipag), originally discovered and synthesized by Nippon Shinyaku, for the treatment of pulmonary arterial hypertension. Uptravi is indicated for the treatment of idiopathic PAH, heritable PAH, PAH associated with connective tissue disease, PAH...
↧